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Abstract Denys–Drash syndrome (DDS) is characterized
by progressive glomerulopathy caused by diffuse mesangial
sclerosis (DMS), genitourinary defects, and a higher risk of
developing Wilms’ tumor. It is commonly assumed that the
DMS is unresponsive to any medications. In this report, we
present a patient with Denys–Drash syndrome, in whom the
cyclosporine A (CsA) was found to induce total remission.
This observation and observations of other authors confirm
that in genetic forms of nephrotic syndrome, the proteinuric
effect of CsA may be due to a non-immunologic mecha-
nism. We confirm the beneficial effect of CsA treatment in
DDS; however, the potential nephrotoxicity of this drug
will probably not allow long-term use.
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Introduction
Nephrotic syndrome in the first year of life in two thirds of
cases is caused by mutations in four genes (NPHS1, NPHS2,
WT1, and LAMB2)[10]. The Wilms’ tumor suppressor gene
1 (WT1) encodes a transcription factor involved in kidney
and gonadal development [19]. Heterozygous de novo
mutations in WT1 gene cause Denys–Drash syndrome
(DDS) and Frasier syndrome (FS), two syndromes charac-
terized by nephrotic syndrome (NS) with either diffuse
mesangial sclerosis (DMS) in DDS or focal segmental
glomerulosclerosis (FSGS) in FS, genitourinary defects and
a higher risk of developing Wilms’ tumor in DDS, or
gonadal dysgerminoma in both DDS and FS [13].
Gellermann et al. [8] recently published three children
with FSGS on renal biopsy and WT1 mutations, who
responded to intensified therapy consisting of oral cyclo-
sporine A (CsA) in combination with oral or intravenous
glucocorticoids. CsA has been used in the treatment of
idiopathic syndrome for 20 years [14]. The mechanism of
CsA action in minimal change disease was the inhibition
of nuclear factor of activated T cell (NFAT) signaling in T
lymphocytes [15]. However, the therapeutic effect of CsA
in genetic nephrotic syndrome is probably related to a
direct influence of CsA on podocytes.
In this report, we present a patient with Denys–Drash
syndrome, in whom the calcineurin inhibitors were found to
induce total remission.
Case report
Our patient is the first child of non-consanguineous young
parents (mother 32, father 34 years) without any past
medical history of kidney diseases. The pregnancy was
uneventful. The infant was born at 41 weeks’ gestation
(birth weight 3,450 g, length 55 cm). The delivery and
neonatal period were normal. At the age of 7 months, she
was hospitalized for the first time in the Pediatric
Nephrology Department because of proteinuria and hema-
turia, which was found in routine urinalysis performed
before the vaccination.
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Physical examination revealed no edema, normal female
external genitalia, and normal body weight and height for
chronological age. Blood pressure was 93/49 mmHg and
pulse was 120 beats per minute.
Initial laboratory investigations revealed variable non-
selective proteinuria 200–960 mg/dl in morning sample,
protein/creatinine ratio 27 g/g, hypoproteinemia (4.79 g/dl),
hypoalbuminemia (3.0 g/dl), hypercholesterolemia
(299 mg/dl), thrombocytosis (567×10
3/μl), and reduced
levels of IgG and IgA.
The serum creatinine level was 0.23 mg/dl, urea was
8 mg/dl, and the glomerular filtration rate was 133 ml/min/
1.73 m
2 by the Schwartz formula. Antinuclear antibodies
were negative, and the level of C3 and C4 were within
normal limits. Congenital nephrotic syndrome was sus-
pected. The ultrasound of the kidneys showed inhomoge-
neous parenchymal hyperechogenicity. Any image
consistent with renal tumor was not seen.
Chromosomal analysis demonstrated karyotype 46, XX,
and the biopsy of the kidney demonstrated diffuse mesangial
proliferation and diffuse fibrillar increase, what may represent
early stage of diffuse mesangial sclerosis. The glomerular
lesions contained high amount of fibrils in the mesangial
matrixwithdiffusemesangialproliferation.Thecapillarywalls
were covered with hypertrophied podocytes. The glomerular
basement membranes were thickened. A few tubules showed
microcystic dilatation. Few pseudotubular structures in endo-
thelial cells were found. Immunofluorescence on frozen
sections using rabbit polyclonal antisera against human IgG,
I g A ,I g M ,a n dC 3r e v e a l e do n l yw e a ks e g m e n t a lI g Ms t a i n i n g .
The molecular genetic analysis was performed in the
laboratory at the University of Michigan in the USA.
Mutation analysis of exons 8 to 9 of WT1 was performed,
and the mutation R394W (c. 1180 C>T) was found in our
patient. No WT1 gene mutations were found in the parents
of the affected child.
The treatment with enalapril (1.25 mg/day), which was
started after the admission and was continued for 11 months,
did not change the proteinuria significantly. There was no
reduction in proteinuria after 4-week oral prednisone
treatment (60 mg/m
2/day). Seven months later, we started
the therapy with CsA (6 mg/kg/24 h in two divided doses).
After 2 months of CsA treatment, partial remission was
observed. The serum albumin level rose and proteinuria
declined. The pre-dose/trough (C0) CsA level was
104.4 ng/ml. After 6 months of CsA treatment, complete
remission was achieved. There was no proteinuria. The
serum total protein was (6.47 mg/dl), albumin (4.26 mg/dl),
cholesterol 197 mg/dl, and platelet count 385×10
3/ql.
Creatinine level was 0.32 mg/dl and the glomerular
filtration rate was 147 ml/min/1.73 m
2. The pre-dose/trough
(C0) CsA level was 95.03 ng/ml.
At the 6 month of the treatment, we decided for CsA
dose reduction to 4.5 mg/kg, but a month later, slight
proteinuria was observed. Now CsA treatment is continued
with the higher dose (6 mg/kg/24 h). The patient is under
the regular control of The Pediatric Nephrology Depart-
ment. She has no proteinuria. Serum creatinine level is
normal. The ultrasonography examination, performed every
3 months, has not revealed any signs of tumor. A control
kidney biopsy is planned soon.
Discussion
We report the benefits of CsA treatment of the patient with
glomerulopathy associated with WT1 mutation as seen in
Denys–Drash syndrome. The girl in this report had early-
onset SRNS secondary to DMS, what was confirmed in
kidney biopsy. Genetic studies showed mutations in intron 9
ofWT1genec.1180C>T.Thisisthemostcommonmutation
found in DDS [8]. Mutations in exons 8 and 9 of the WT1
gene have been found in patients with isolated SRNS and in
SRNS associated with Wilms’ tumor or urogenital malfor-
mations. The data presented by Mucha et al. [16]i n d i c a t e d
that screening of WT1 exons 8 and 9 in patients with
sporadic SRNS is sufficient to detect pathogenic WT1
mutations. Our patient lacked any evidence of anomaly of
the kidney or urogenital tract. No renal tumor has not been
seen so far. It is possible that our patients have an incomplete
form of DDS; however, it corresponds to the observation of
Ismaili et al. [11], who reported the presence of Wilms’
tumor in only one of two patients with DDS. Chernin et al.
[5] in the recent publication suggested that missense
mutations can occur with and without Wilms’ tumor.
In our patient, the diagnosis of DDS was done in the
eighth month of life. The girl fulfilled the criteria of
SRNS. In this situation, CsA therapy was started with a
significant reduction of proteinuria and remission of
nephrotic syndrome. Three months later, complete remis-
sion of proteinuria was found.
Whereas genetic forms of nephrotic syndrome do not
respond to therapy with immunosuppressive drugs, partial
remission has been reported following therapy with
calcineurin inhibitors in patients with NPHS2 [12], Frasier
syndrome [8], mutations of the phospholipase C epsilon
gene (PLCE1) [9], and Alport syndrome [3, 4]. Gellermann
et al. [8] reported three children with FSGS associated with
WT1 mutation treated with combined CsA and prednisone
therapy given for 6 and 12 months. In long-term observa-
tion, the authors observed remission of NS and significant
reduction of proteinuria. Our patient was treated with CsA
alone and we observed complete remission of proteinuria.
This is interesting because it was considered that DMS was
unresponsive to any medications [20].
390 Eur J Pediatr (2011) 170:389–391The therapy does not seem to be accompanied by a
significant loss of renal function on the short term. We plan
to continue the treatment with the lowest possible dose
which controls the proteinuria. A control kidney biopsy to
check for CsA nephrotoxicity will be done soon.
Calcineurin is a ubiquitously expressed serine/threonine
phosphatase [1]. It was considered that the main effect of
CsA treatment in nephrotic syndrome caused by T cell
dysfunction was the inhibition of NFAT signaling in T cells
[6]. However, it was found that CsA can also reduce
proteinuria in non-immunological diseases, raising doubts
about the above hypothesis. In genetic diseases, mecha-
nisms other than the immunosuppressive effects are
involved in reduction of proteinuria. Similarly, the afferent
arteriole vasoconstriction, which is induced by CsA, does
not seem to play the main role in the reduction of
proteinuria. This fact was suggested by Zietse et al. [21],
who studied the influence of CsA on proteinuria in different
glomerulopathies and found the reduction of protein
excretion in minimal change disease, but not in membra-
noproliferative glomerulonephritis or FSGS. The possible
mechanism in genetic NS may be that proposed by Faul et
al. [7]. The authors suggested the influence of CsA on
synaptopodin, an actin binding protein that was highly
expressed in podocytes. It is also an important regulator of
podocyte function through its interaction with CD2AP [2].
It was shown that calcineurin caused the dephosphorylation
of synaptopodin and caused proteinuria via its degradation.
In this situation, CsA therapy leads to the stabilization of its
actin cytoskeleton. This mechanism seems to be possible
because significant reduction (30%) of CsA dose caused the
slight proteinuria in our patient, so we increased the dose to
initial one. Our observation seems to confirm the theory of
Mundel and Reiser, who suggested that proteinuria is due to
an enzymatic disease of the podocytes [18]. It is likely that
podocytes are a direct target of CsA, which preserves the
phosphorylation-dependent synaptopodin-14-3-3beta inter-
action, protects synaptopodin from degradation, and pre-
serves a stable filtration barrier [7, 17].
ThefactthattheantiproteinuriceffectofCsAresultsfroma
direct effect on podocytes explains not only its beneficial role
in most steroid-resistant and steroid-dependent nephrotic
syndromes but also the fact of cyclosporine dependency.
Ourobservationandobservationsofotherauthors[3, 4, 9, 12,
15] confirm the beneficial effect of CsA treatment in genetic
NS; however, the potential nephrotoxicity of this drug will
probably not allow the long-term use.
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